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Abstract
The discovery of insulin and its subsequent mass manufacture transformed the lives of people with type 1 and 2 diabetes. Insulin,
however, was a drug with a ‘dark side’. It brought with it the risk of iatrogenic hypoglycaemia. In this short review, the cellular
consequences of recurrent hypoglycaemia, with a particular focus on the brain, are discussed. Using the ventromedial hypothal-
amus as an exemplar, this review highlights how recurrent hypoglycaemia has an impact on the specialised cells in the brain that
are critical to the regulation of glucose homeostasis and the counterregulatory response to hypoglycaemia. In these cells, recurrent
hypoglycaemia initiates a series of adaptations that ensure that they are more resilient to subsequent hypoglycaemia, but this leads
to impaired hypoglycaemia awareness and a paradoxical increased risk of severe hypoglycaemia. This review also highlights
how hypoglycaemia, as an oxidative stressor, may also exacerbate chronic hyperglycaemia-induced increases in oxidative stress
and inflammation, leading to damage to vulnerable brain regions (and other end organs) and accelerating cognitive decline. Pre-
clinical research indicates that glucose recovery following hypoglycaemia is considered a period where reactive oxygen species
generation and oxidative stress are pronounced and can exacerbate the longer-term consequence of chronic hypoglycaemia. It is
proposed that prior glycaemic control, hypoglycaemia and the degree of rebound hyperglycaemia interact synergistically to
accelerate oxidative stress and inflammation, which may explain why increased glycaemic variability is now increasingly
considered a risk factor for the complications of diabetes.
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Introduction
This year is the centenary of the discovery of insulin by
Frederick Banting and Charles Best in Professor John
Macleod’s department in Toronto (ON, Canada) in the
summer of 1921. There can be little doubt about the impact
of their discovery, which has transformed the lives of millions
of people with both type 1 and 2 diabetes in the 100 years
since. At the same time, it was soon discovered that insulin
therapy was not without risk. Physicians reported that exoge-
nous insulin, when delivered in excess, led to a low blood
glucose; the ‘hypoglycaemic reaction’. It was also soon appar-
ent that repeated exposure to low glucose led to, ‘reactions
[that] differ so much from the original ones that patients
became dangerously unaware of their onset’ [1].
Glucose homeostasis is fundamental to survival in most
vertebrate species. As such, we have evolved a number of
counterregulatory mechanisms designed to restore glucose
homeostasis when glucose levels fall below the normal range.
Over the last few decades, we have learnt that, in humans,
there exists an integrated network of specialised glucose-
sensing cells, found in certain key parts of the brain and in
the periphery, that are able to monitor and respond to
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prevailing glucose levels, as well as integrate glucose homeo-
stasis with other aspects of whole-body energy status [2, 3].
We also recognise that, in response to recurrent
hypoglycaemia, these specialised glucose-sensing cells adapt,
leading (through mechanisms still not entirely worked out) to
a clinical syndrome called impaired awareness of
hypoglycaemia. Moreover, there is increasing evidence that,
in addition to making individuals susceptible to severe
hypoglycaemia, these adaptations may also have conse-
quences in terms of end-organ disease. In this short review, I
will briefly discuss the cellular consequences of
hypoglycaemia, focusing on the impact of recurrent
hypoglycaemia in the brain. This will be illustrated by
outlining the ways in which recurrent hypoglycaemia affects
cells in glucose-sensing regions of the brain (leading to
impaired awareness of hypoglycaemia and severe
hypoglycaemia), as well as how recurrent hypoglycaemia
may affect other brain regions, potentially amplifying the
tissue damage that results from chronic hyperglycaemia.
Bringing light to the dark side of insulin
Dr Philip Cryer used his 1994 Banting Lecture to the
American Diabetes Association to introduce the concept of
hypoglycaemia-associated autonomic failure (HAAF). Cryer
outlined a series of seminal physiological studies that
described how, in humans, antecedent iatrogenic
hypog l y c a em i a r e s u l t e d i n d e f e c t i v e g l u co s e
counterregulation (through reducing catecholaminergic
responses to a given level of subsequent hypoglycaemia)
and impaired awareness of hypoglycaemia (by reducing
sympathoadrenal and symptom responses to a given level of
subsequent hypoglycaemia), thereby setting up a vicious cycle
whereby hypoglycaemia begets hypoglycaemia [4].
Subsequently, Dr Robert Sherwin, in his 2007 Banting
Lecture, ‘Bringing light to the dark side of insulin: a journey
across the blood-brain barrier’, described over three decades
of research in which, using human and animal models, he and
his research group had done much to help us understand how
the brain detects and responds to hypoglycaemia [5].
Using the ventromedial hypothalamus (VMH) as an exem-
plar for a glucose-sensing region, Sherwin proposed that
glucose-sensing neurons operated in a way that appeared to
parallel the pancreatic islet [5]. In this model, like pancreatic
beta and alpha cells, neurons in the brain respond to blood
glucose levels. More specifically, glucose-excited and
glucose-inhibited neurons respond to high and low blood
glucose levels, respectively, in a coordinated manner. The
key steps in the process of transducing the glucose signal to
an alteration in neural firing rates involve sulfonylurea recep-
tor 1 (SUR1), ATP-sensitive potassium (KATP) channels,
glucokinase and AMP-activated protein kinase (AMPK) [5].
Glucokinase is a critical component of this signalling mecha-
nism because its activity is proportional to glucose concentra-
tions. As glucose rises, therefore, so does glucokinase activity,
ultimately leading to an increased ATP:AMP ratio.
Supporting the role for glucokinase in glucose sensing in the
brain, mice and humans with reduced glucokinase activity
show an exaggerated response to hypoglycaemia [6], while
glucokinase activation in hypothalamic glucose-excited
neurons reverses the hyperpolarising effect of low glucose
[7]. Subsequently, the increased ATP:AMP ratio with
increased glucokinase activity results in closure of KATP chan-
nels, depolarising the neurons and increasing their firing rate
[8]. A role for KATP channels in brain glucose sensing has
been demonstrated in cells, hypothalamic slice preparations,
transgenic mice, in vivo studies in rats [9], and humans with
type 1 diabetes and impaired awareness of hypoglycaemia
[10]. Similarly, pharmacological or genetic manipulation of
AMPK in neurons or the VMH is able to increase or decrease
the counterregulatory response to hypoglycaemia [5, 9].
Discussion of other transporters, membrane channels or
enzymes that contribute to glucose sensing, such as sodium–
glucose cotransporters (SGLTs), transient receptor potential
channels, Na+/K+ ATPase, K+ channels and nitric oxide
synthase (NOS), are beyond the scope of this review, but
interested readers are referred to a recent very detailed review
of this area by Stanley et al [8]. Sherwin proposed that it was
through the key signalling steps described above that a falling
glucose level led to suppression of glucose-excited gamma
aminobutyric acid (GABA)-inhibitory neurons, and activation
of glutamatergic glucose-inhibited neurons, leading to
progressive activation of the downstream counterregulatory
response.
This hypothesis subsequently served as a model for exam-
ining the consequences of recurrent hypoglycaemia on
glucose-sensing neurons. Electrophysiological studies
demonstrated that recurrent hypoglycaemia resulted in a left-
shift in glucose-excited neurons so that they did not
hyperpolarise until glucose levels fell further [11]. This was
consistent with reports of increased hypothalamic hexokinase
activity following recurrent hypoglycaemia [12], implying
that glucose-excited neurons were better able to maintain
intercel lular ATP:AMP ratios during subsequent
hypoglycaemia and, hence, maintain GABAergic tone in the
VMH [13]. A likely candidate mechanism for this was an
increase in glycolytic flux in neurons. Rodent studies had
shown that recurrent hypoglycaemia led to increased glucose
transport activity at the blood–brain barrier (BBB) via an
increase in total BBB GLUT1 and an increased transporter
concentration at the luminal surface [14]. Similarly, in vivo
microdialysis of brain extracellular fluid found higher glucose
levels in rodents exposed to recurrent hypoglycaemia
compared with control animals [15]. However, human studies
using magnetic resonance spectroscopy or positron emission
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tomography (PET) have produced conflicting data about the
effects of recurrent hypoglycaemia on cerebral glucose uptake
andmetabolism. This may reflect regional variation in glucose
metabolism, or even differences in how neurons and glial cells
individually respond to recurrent hypoglycaemia [8, 16, 17].
Alternatively, recurrent hypoglycaemia may induce
cellular adaptations that allow lactate or ketones to be
used as alternate fuels [8, 17]. Lactate or ketone infusions
suppress counterregulation to systemic hypoglycaemia in
humans [8], and lactate transport and lactate metabolism
by the brain are thought to be increased in both humans
[18, 19] and rodents [20] who have been exposed to
recurrent hypoglycaemia. Initial research also suggested
that recurrent hypoglycaemia led to increased astrocytic
glycogen storage (supercompensation), which could
p rov i d e add i t i ona l l a c t a t e du r i ng sub s equen t
hypoglycaemia, although these findings were not replicat-
ed in later studies [8]. Lactate might act to modulate the
counterregulatory response to hypoglycaemia via suppres-
sion of AMPK [21] and increased GABA release [22].
However, other studies in humans [23] and rodents [20]
suggest that lactate may be insufficient to support metab-
olism during hypoglycaemia and might instead act as a
regulator of glucose metabolism, indicating that the alter-
nate fuel hypothesis cannot fully explain how the brain
adapts to recurrent hypoglycaemia.
In addition to changes in cellular fuel transport and metab-
olism in glucose-sensing neurons, a number of other factors
have been proposed that could contribute, at least in part, to
the development of impaired hypoglycaemia awareness (Fig.
1). External neuronal modulators, such as opioids, serotonin,
steroids, cytokines or urocortin, have all been shown to modu-
late the counterregulatory response to insulin-induced
hypoglycaemia and can affect changes in neurotransmitter
synthesis or release, or changes in synaptic structure [2, 8].
More recently, it has also been proposed that the whole-
organism response to recurrent hypoglycaemia represents a
form of adaptive memory, referred to as ‘habituation’ [2].
This concept was tested by using a single challenge of high-
intensity exercise as a dishabituatory stimulus to restore
hypoglycaemic responses in rodents [24] and humans [25]
with defective counterregulation. Stable isotope labelling with
amino acids in cell culture (SILAC) mass spectroscopy iden-
tified a potential role for exercise-induced brain-derived
neurotrophic factor (BDNF) in restoring hypothalamic
glutaminergic transmission.
In summary, recurrent hypoglycaemia may directly or indi-
rectly lead to a series of adaptations in specialised glucose-
sensing cells throughout the body, the net effect of which is to
reduce the responsiveness of these cells to subsequent
hypoglycaemia (a ‘left-shift’ in the counterregulatory
response to subsequent hypoglycaemia; Fig. 2). Although this
is considered an adaptive response, likely to be a mechanism
to ensure the cells remain resilient to future periods of energy
deprivation, this proves ‘maladaptive’ in diabetes, largely
because of the inability to switch off exogenous insulin that
is being released continuously from a subcutaneous depot, but
also because of a hypoglycaemia-specific defect in alpha cell-
derived glucagon release that is present in all people with type
1 diabetes after a few years of diagnosis and in some people
with long-duration type 2 diabetes [9]. As a consequence,
recurrent hypoglycaemia in diabetes leads both to impaired
awareness of hypoglycaemia and a greatly increased risk of
severe hypoglycaemia.
Recurrent hypoglycaemia
and the ‘pathobiology of diabetes
complications’
The first part of this review described how recurrent
hypoglycaemia induces a series of cellular adaptations in
key glucose-sensing neurons that ultimately leads to their
reduced responsiveness to low glucose levels. This effect is
not specific to glucose-sensing neurons because the impact of
recurrent hypoglycaemia is seen on cognitive functions and
emotion, indicating cells in other brain regions are also affect-
ed [2]. This raises the question as to what the long-term effects
of recurrent hypoglycaemia may be with regards to other
aspects of brain function. Interestingly, while for many people
with type 1 and 2 diabetes strict avoidance of hypoglycaemia
can restore hypoglycaemia awareness [2], there remains a
cohort of individuals who have complete and irreversible loss
of awareness, which suggests sustained tissue damage.
Epidemiological research on the long-term impact of
hypoglycaemia on the brain is limited, largely because most
studies are only able to examine the association between
severe hypoglycaemia and cognitive performance or brain
structure. Moreover, most cases of severe hypoglycaemia do
not result in hospitalisation or even ambulance call-out and,
so, are under-recorded in healthcare databases, and the vast
majority of hypoglycaemic episodes are not severe in nature.
That being said, the various meta-analyses examining the
impact of severe hypoglycaemia on brain structure and func-
tion indicate a small negative effect on a number of different
cognitive domains, especially with early-onset type 1 diabetes
[26, 27]. There is also evidence of structural changes in the
brain in adults with type 1 diabetes who have impaired aware-
ness of hypoglycaemia [28].
The brain is considered especially vulnerable to
hypoglycaemia. This is due to its high metabolic demand,
reliance on glucose as a primary fuel and minimal fuel stores.
Rodent studies have demonstrated that severe hypoglycaemia
results in significant brain damage through a number of mech-
anisms, including activation of neuronal glutamate receptors,
production of reactive oxygen species (ROS), neuronal zinc
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Fig. 1 Potential mechanisms of cerebral adaptation to recurrent
hypoglycaemia. This figure highlights some of the major mechanisms
that have been shown to contribute to the suppression of
counterregulatory responses that follows recurrent hypoglycaemia. In
particular, research has highlighted potential roles for: (1) increased
glucose transport; (2) increased use of alternate fuels; (3) gliotransmitters,
such as cytokines; (4) increased phosphorylation and metabolism of
glucose; (5) external neuronal modulators; (6) alterations in neurotrans-
mitter release; and (7) peripheral signalling molecules, such as glucocor-
ticoids. βAdR, β-adrenergic receptor; EphA5, ephrin receptor A5; GK,
glucokinase; NorEpi, noradrenaline (norepinephrine); SGLT, sodium–
glucose cotransporters; TRP, transient receptor potential channels. This
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Fig. 2 Shifting thresholds for hypoglycaemia detection. In this hypothet-
ical model, in people without diabetes (represented by the black line), a
progressive fall in blood glucose leads to gradual suppression of glucose-
excited neuronal activity and an associated increase in glucose-inhibited
neuronal activity, up to a maximum response. Recurrent (or chronic)
hypoglycaemia leads to a left shift of this response curve (red line), while
chronic hyperglycaemia leads to a right shift (blue line), both altering the
threshold for initiating a counterregulatory hormone response to subse-
quent hypoglycaemia. Figure adapted from [2]. This figure is available as
part of a downloadable slideset
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release, activation of poly(ADP-ribose) polymerase–1, and
mitochondrial permeability transition, with oxidative DNA
damage thought to be the critical endpoint of hypoglycaemic
stress (e.g., [29–31]). However, the degree of hypoglycaemia
induced in these studies is extreme (usually <1.0 mmol/l
glucose and sufficient to produce an isoelectric EEG) and,
fortunately, this is seen rarely in humans with diabetes, albeit
with an equally poor outcome.
A number of recent studies have examined the impact of
recurrent moderate (2.5–3.5 mmol/l blood glucose)
hypoglycaemia over a period of 2–4 weeks in rodent models
of type 1 diabetes [32–34]. Recurrent hypoglycaemia was
shown to exacerbate impairments in memory function that
resulted from chronic hyperglycaemia [32, 34]. All three of
these studies reported similar findings on examination of
hippocampal tissue; recurrent hypoglycaemia in diabetic, but
not non-diabetic, rodents resulted in disruptions of mitochon-
drial structure, dynamics and membrane potential, as well as
alterations in mitochondrial energy metabolism. Evidence of
increased oxidative stress and oxidative damage was also
present, as well as increased ROS production, reduced antiox-
idant activity and increased inflammation [32–34]. There was
also evidence of changes in synaptic morphology and reduced
synaptic marker proteins [32–34]. Interestingly, recurrent
moderate hypoglycaemia in non-diabetic rodents does not
result in cognitive impairment or hippocampal damage [34]
and, in a long-term study, it actually enhanced cognitive
performance [35]. This implies that recurrent moderate
hypoglycaemia is associated with oxidative damage only in
the context of diabetes.
Chronic hyperglycaemia is well recognised as having
profound effects on many cell types. As described by
Michael Brownlee in his 2004 Banting Lecture, the
‘Pathobiology of diabetes complications: a unifying mecha-
nism’, hyperglycaemia leads to an overproduction of mito-
chondrial superoxide, resulting in protein kinase c (PKC) acti-
vation, increased advanced glycation end-products (AGE),
increased hexosamine pathway activity and increased flux
through the polyol pathway, leading to cellular damage and
inflammation [36]. This chronic stimulation impairs cellular
antioxidant responses; people with diabetes have reduced
erythrocyte super oxide dismutase (SOD) [37, 38] and
reduced total free-radical trapping capacity [39]. Chronic
hyperglycaemia, therefore, induces chronic oxidative stress/
inflammation and depletes host antioxidant defence mecha-
nisms. Moreover, hypoglycaemia is both a proinflammatory
stimulus and induces oxidative stress [40]. Therefore, the abil-
ity of cells to cope with hypoglycaemia-induced oxidative
stress may be impaired in diabetes. Consistent with this,
severe hypoglycaemia in chronically hyperglycaemic rodents
induces more neuronal damage than in non-diabetic rodents
[30], and diabetes acts synergistically with recurrent
hypoglycaemia to impair mitochondrial function and induce
oxidative damage in rodents [32–34]. Furthermore,
hypoglycaemia-induced oxidative stress and neuronal death
have been shown to occur primarily in the recovery period,
during glucose reperfusion, and superoxide production and
neuronal death increased with increasing glucose concentra-
tions during the reperfusion period [41]. Based on these find-
ings (summarised in Fig. 3) it is possible to speculate that the
consequences of hypoglycaemia in vulnerable brain regions,
such as the hippocampus are dependent not only on the extent
of hypoglycaemia, but also the quality of prior glycaemic
control and the extent of rebound hyperglycaemia on recovery
from the hypoglycaemic episode.
Summary
The value of insulin in the management of diabetes and the
evidence in support of intensive insulin therapy targeting near-
normalisation of glycaemic control to minimise the micro- and
macrovascular complications of diabetes is overwhelming.
However, hypoglycaemia remains a relatively common adverse
effect of insulin therapy that has consequences for the individual
and their carers. Asides from the immediate cognitive and
emotional impacts of acute hypoglycaemia, impaired
hypoglycaemia awareness is a consequence of repeated expo-
sure to hypoglycaemia that carries a high risk for severe
hypoglycaemia. Epidemiological and pre-clinical research also
indicates that recurrent hypoglycaemia may exacerbate chronic
hyperglycaemia-induced increases in oxidative stress and
inflammation, leading, in particular, to damage in vulnerable
brain regions and accelerated cognitive decline.
There remain many unanswered questions that hopefully
future research will be able to shed light on. For instance, do
the effects of recurrent hypoglycaemia on specialised glucose-
sensing neurons occur through a single signalling defect or
multiple pathways given the complexity of the hypoglycaemic
response? Moreover, is there actually a ‘defect’ in sensing or
are glucose-sensing neurons just less responsive to low
glucose? If the latter, do the major changes specifically occur
in the specialised neuron or in the periphery (e.g., adrenal
gland)? It is also uncertain whether these effects are reversible
in all people through strict hypoglycaemic avoidance or
whether, in some, these may prove irreversible as a conse-
quence of long-term damage to critical components of this
homeostatic defence mechanism.
When we consider other consequences of recurrent
hypoglycaemia on the brain, we also need clarity on the actual
level of hypoglycaemia that is clinically significant, which
may or may not be 3.0 mmol/l as recently proposed by the
International Hypoglycaemia Study Group [42]. It is also
possible that recurrent hypoglycaemia has consequences in
other metabolically active tissues, such as the heart and
kidney, whereby the interaction between prior glycaemic
Diabetologia
control, hypoglycaemia and the degree of rebound
hyperglycaemia may explain why increased glycaemic vari-
ability is considered a risk factor for complications in multiple
organ systems [43].
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